Leave a little sharper than you arrived.

News, calculators, learning and daily puzzles — pick any one and leave a little further along.

Today’s puzzle

Rusfertide earns FDA approval and NCCN Category 1 status, transforming polycythemia vera care

A new era for polycythemia vera treatment has arrived. Rusfertide (Mimrylo), a first-in-class hepcidin mimetic, received FDA approval in August 2026 and is now a Category 1 NCCN recommendation for both low- and high-risk PV. Phase 3 VERIFY trial data show 77% of patients achieved clinical response vs. 33% on placebo, with dramatically fewer phlebotomies needed.

Cancer Therapy Advisor · 2 min

FDA expands talazoparib + enzalutamide approval to earlier-stage metastatic prostate cancer

OncLive · 2 min

Tarlatamab rewrites the rulebook for small cell lung cancer — twice

Medscape · 3 min

ACOG draws the line on GLP-1s in pregnancy — here's what clinicians need to know

Everything on Curie.MD

NeurologyPlay & LearnLearn what’s new in your field, a few minutes at a time.Start learning CardiologyCalculatorsEnter the case once. See every relevant score, side by side.Open a calculator All fieldsDaily GamesThree new clinical puzzles every morning.Play today

Get Curie’s Weekly Dose

What changed in clinical practice, policy, and coverage, and what it means for your patients.

Subscribe free Free. Weekly. Unsubscribe anytime.